BioAtla (BCAB) Shares Outstanding (2020 - 2026)
BioAtla (BCAB) posted quarterly Shares Outstanding (Entity) of $1.7 million for Q1 2026, up 42.09% year-over-year from $1.2 million in Q1 2025, and up 30.75% quarter-over-quarter from $1.3 million in Q4 2025.
BioAtla (BCAB) Shares Outstanding (2020 - 2026) Analysis & Trends
BioAtla's Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 42.09% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 42.09% YoY), while the FY2025 annual figure was $1.3 million, up 9.23% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $1.7 million, up from $1.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $1.7 million in Q1 2026, with the low at $717826.0 in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $962126.0 (2024), against an average of $1.0 million.
- The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) climbed 0.91% in 2024, then soared 42.09% in 2026.
- BioAtla's Shares Outstanding (Entity) stood at $926723.0 in 2022, then advanced by 3.76% to $961552.0 in 2023, then rose by 20.84% to $1.2 million in 2024, then rose by 9.23% to $1.3 million in 2025, then soared by 30.75% to $1.7 million in 2026.
- Business Quant data shows BCAB's Shares Outstanding (Entity) at $1.7 million in Q1 2026, $1.3 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 1.50 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 971,467.00 |
| Sep 30, 2024 | 966,717.00 |
| Jun 30, 2024 | 964,298.00 |
| Mar 31, 2024 | 961,749.00 |
| Dec 31, 2023 | 955,551.00 |
| Sep 30, 2023 | 956,682.00 |
| Jun 30, 2023 | 954,129.00 |
| Mar 31, 2023 | 951,568.00 |
| Dec 31, 2022 | 778,545.00 |
| Sep 30, 2022 | 750,335.00 |
| Jun 30, 2022 | 748,407.00 |
| Mar 31, 2022 | 746,447.00 |
| Dec 31, 2021 | 691,225.00 |
| Sep 30, 2021 | 678,189.00 |